OTCMKTS:TXSP - Taxus Pharmaceuticals Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$3.16 0.00 (0.00 %)
(As of 08/15/2018 04:00 PM ET)
Previous Close$3.16
Today's Range$3.16 - $3.16
52-Week Range$3.16 - $3.16
Volume46 shs
Average VolumeN/A
Market Capitalization$257.54 million
P/E RatioN/A
Dividend YieldN/A
Taxus Pharmaceuticals Holdings, Inc. manages and operates health and wellness stores. Its products include dietary supplements, vitamins, minerals, calcium, fibers, proteins and sport nutrition items. The company was founded on January 2, 2002 and is headquartered in Little Neck, NY.

Receive TXSP News and Ratings via Email

Sign-up to receive the latest news and ratings for TXSP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug stores & proprietary stores


Debt-to-Equity RatioN/A
Current Ratio0.29
Quick Ratio0.29


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales25,754.00
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net Income$-110,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-1,076.15%


Outstanding Shares81,500,000
Market Cap$257.54 million

Taxus Pharmaceuticals (OTCMKTS:TXSP) Frequently Asked Questions

What is Taxus Pharmaceuticals' stock symbol?

Taxus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TXSP."

When is Taxus Pharmaceuticals' next earnings date?

Taxus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, October, 5th 2018. View Earnings Estimates for Taxus Pharmaceuticals.

Who are some of Taxus Pharmaceuticals' key competitors?

Who are Taxus Pharmaceuticals' key executives?

Taxus Pharmaceuticals' management team includes the folowing people:
  • Jia Yue Zhang, Chairman, President, Chief Executive Officer & CFO

Has Taxus Pharmaceuticals been receiving favorable news coverage?

Media headlines about TXSP stock have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Taxus Pharmaceuticals earned a media and rumor sentiment score of 0.04 on Accern's scale. They also gave news headlines about the company an impact score of 46.22 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Taxus Pharmaceuticals.

How do I buy shares of Taxus Pharmaceuticals?

Shares of TXSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taxus Pharmaceuticals' stock price today?

One share of TXSP stock can currently be purchased for approximately $3.16.

How big of a company is Taxus Pharmaceuticals?

Taxus Pharmaceuticals has a market capitalization of $257.54 million and generates $10,000.00 in revenue each year.

How can I contact Taxus Pharmaceuticals?

Taxus Pharmaceuticals' mailing address is 23605 BRADDOCK AVENUE, BELLEROSE NY, 11426. The company can be reached via phone at 718-631-1522.

MarketBeat Community Rating for Taxus Pharmaceuticals (OTCMKTS TXSP)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about Taxus Pharmaceuticals and other stocks. Vote "Outperform" if you believe TXSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.